Revenue

12 Months Ended

Dec. 31, 2020

23.

Revenue

The Company’s revenue is solely from contracts with customers and is comprised of revenue from the sale of cannabis. Cannabis revenue is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers.

	Year ended December 31		Year ended December 31		Ten months ended December 31
	2020		2019		2018
Provincial boards		55,315		13,386		—
Medical		32		24		—
Licensed producers		17,974		53,517		—
Gross revenue⁽¹⁾		73,321		66,927		—

(1)

The Company had four major customers each with revenue in excess of 10% of total cannabis revenue. Sales to major customers totaled $43.9 million for the year ended December 31, 2020 (December 31, 2019 – four major customers with sales of $40.7 million). Only one major customer had sales exceeding 10% of total cannabis revenue for both periods.

The following table disaggregates revenue by form for the periods noted:

	Year ended December 31		Year ended December 31		Ten months ended December 31
	2020		2019		2018
Revenue from dried flower		51,424		58,246		—
Revenue from vapes		18,447		504		—
Revenue from oil		3,145		8,177		—
Revenue from edibles		263		—		—
Revenue from concentrates		42		—		—
Gross revenue		73,321		66,927		—

The Company has recognized the following receivables from contracts with customers:

	December 31, 2020			December 31, 2019			December 31, 2018
Receivables, included in 'trade receivables' (note 7)		15,786			20,281			209

Receivables from contracts with customers are typically settled within 30 days. As at December 31, 2020, an impairment reversal of $0.5 million (December 31, 2019 - $0.6 million loss) has been recognized on receivables from contracts with customers (note 30).